These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 22862686

  • 1. Emerging treatment for chronic migraine and refractory chronic migraine.
    Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, Simmaco M, Smith T, Al-Kaisy A, Arcioni R, Martelletti P.
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):393-406. PubMed ID: 22862686
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Emerging migraine treatments and drug targets.
    Olesen J, Ashina M.
    Trends Pharmacol Sci; 2011 Jun; 32(6):352-9. PubMed ID: 21459461
    [Abstract] [Full Text] [Related]

  • 5. New therapeutic developments in chronic migraine.
    Lovell BV, Marmura MJ.
    Curr Opin Neurol; 2010 Jun; 23(3):254-8. PubMed ID: 20442572
    [Abstract] [Full Text] [Related]

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 7. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P.
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 9. Management of acute and chronic migraine.
    Coppola G, Schoenen J.
    Curr Opin Support Palliat Care; 2012 Jun 15; 6(2):177-82. PubMed ID: 22406987
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety.
    Szok D, Csáti A, Vécsei L, Tajti J.
    Toxins (Basel); 2015 Jul 17; 7(7):2659-73. PubMed ID: 26193319
    [Abstract] [Full Text] [Related]

  • 11. Future trends in drugs for migraine prophylaxis.
    Barbanti P, Aurilia C, Egeo G, Fofi L.
    Neurol Sci; 2012 May 17; 33 Suppl 1():S137-40. PubMed ID: 22644189
    [Abstract] [Full Text] [Related]

  • 12. Medication overuse and chronic migraine: a critical review according to clinical pharmacology.
    Ferrari A, Baraldi C, Sternieri E.
    Expert Opin Drug Metab Toxicol; 2015 Jul 17; 11(7):1127-44. PubMed ID: 26027878
    [Abstract] [Full Text] [Related]

  • 13. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
    van Hoogstraten WS, MaassenVanDenBrink A.
    J Headache Pain; 2019 May 16; 20(1):54. PubMed ID: 31096904
    [Abstract] [Full Text] [Related]

  • 14. What's new in the migraine attack treatment.
    Lanteri-Minet M.
    Rev Neurol (Paris); 2013 May 16; 169(5):436-41. PubMed ID: 23602496
    [Abstract] [Full Text] [Related]

  • 15. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 16; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 16. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.
    Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A.
    Expert Opin Drug Discov; 2013 Nov 16; 8(11):1309-23. PubMed ID: 23962310
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
    Blumenfeld A, Gennings C, Cady R.
    Headache; 2012 Apr 16; 52(4):636-47. PubMed ID: 22221151
    [Abstract] [Full Text] [Related]

  • 18. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria.
    Zeeberg P, Olesen J, Jensen R.
    Cephalalgia; 2009 Feb 16; 29(2):214-20. PubMed ID: 18823364
    [Abstract] [Full Text] [Related]

  • 19. Similarities and differences between chronic migraine and episodic migraine.
    Ferrari A, Leone S, Vergoni AV, Bertolini A, Sances G, Coccia CP, Ottani A, Pinetti D, Sternieri E.
    Headache; 2007 Jan 16; 47(1):65-72. PubMed ID: 17355496
    [Abstract] [Full Text] [Related]

  • 20. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM.
    Expert Opin Drug Metab Toxicol; 2018 Jan 16; 14(1):25-41. PubMed ID: 29226741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.